Join WhatsApp

Folow Facebook

Subscribe YouTube

Follow Instagram

New Delhi: Domestic generic producers are likely to see near-term gains as higher prices for branded drugs can push demand towards cost-effective alternatives after the US announced its decision to impose 100 per cent tariffs on the pharmaceuticals industry from October 1, analysts said on Friday.

Generic drugs are currently exempted from US tariffs and according to Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance (IPA), the latest tariff announcement is for “branded or patented drugs, and not applicable to generics”.

Domestic pharmaceutical firms supply a substantial proportion of drugs to US residents.

Also Read: GST council likely to address inverted duty structure in notebooks

As per industry sou

See Full Page